Drug recall · May 15, 2024
Duloxetine Delayed-Release Capsules recall
Why: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Duloxetine Delayed-Release Capsules, USP, 20 mg, , 500-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922, NDC 51991-746-05.
- Lots / codes
220456: Exp. Feb 2025
- Quantity
- 7,188/ 500 count bottles
- Company
- Breckenridge Pharmaceutical, Inc, Berlin, CT
- Distribution
- US Nationwide.
- Initiated
- April 29, 2024 · Voluntary: Firm initiated
- Classified
- May 4, 2024
- Reported
- May 15, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Duloxetine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.